Paris – June 26, 2008 – Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, announced the publication of data from a phase 1 dose escalation study evaluating the effects of IL-7 therapy on human lymphocytes in subjects with non-hematologic, nonlymphoid cancer refractory to standard therapy. The results of this study, performed in collaboration with U.S. National Cancer Institute (NCI) investigators lead by Claude Sportès, Crystal Mackall and Ronald Gress, support the potential of the IL-7 investigational product as an immunotherapy for the treatment of patients with impaired immunity due to physiologic (age), iatrogenic (chemotherapy ortransplantation) or pathologic (HIV) lymphodepletion...
... About Cytheris –
Cytheris SA is a privately held clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HCV and HIV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).
The company operates from its headquarters and laboratories in Issy-les-Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland... [PDF] Cytheris' Press Release - PDF du Communiqué de Presse de Cytheris -
